Academic Journal
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
| العنوان: | Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) |
|---|---|
| المؤلفون: | Hayden, P.J., Roddie, C., Bader, P., Basak, G.W., Bonig, H., Bonini, C., Chabannon, C., Ciceri, F., Corbacioglu, S., Ellard, R., Sanchez-Guijo, F., Jäger, U., Hildebrandt, M., Hudecek, M., Kersten, M.J., Köhl, U., Kuball, J., Mielke, S., Mohty, M., Murray, J., Nagler, A., Rees, J., Rioufol, C., Saccardi, R., Snowden, J.A., Styczynski, J., Subklewe, M., Thieblemont, C., Topp, M., Ispizua, Á.U., Chen, D., Vrhovac, R., Gribben, J.G., Kröger, N., Einsele, H., Yakoub-Agha, I. |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2022 |
| المجموعة: | White Rose Research Online (Universities of Leeds, Sheffield & York) |
| الوصف: | Background Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lymphoma. Products for other diseases such as multiple myeloma and follicular lymphoma are likely to be approved by the European Medicines Agency in the near future. Design The European Society for Blood and Marrow Transplantation (EBMT)-Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association collaborated to draft best practice recommendations based on the current literature to support health care professionals in delivering consistent, high-quality care in this rapidly moving field. Results Thirty-six CAR-T experts (medical, nursing, pharmacy/laboratory) assembled to draft recommendations to cover all aspects of CAR-T patient care and supply chain management, from patient selection to long-term follow-up, post-authorisation safety surveillance and regulatory issues. Conclusions We provide practical, clinically relevant recommendations on the use of these high-cost, logistically complex therapies for haematologists/oncologists, nurses and other stakeholders including pharmacists and health sector administrators involved in the delivery of CAR-T in the clinic. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | text |
| اللغة: | English |
| Relation: | https://eprints.whiterose.ac.uk/187848/1/Hayden%20et%20al%20EBMT%20EHA%20CART%20Guidelines%202022.pdf; Hayden, P.J., Roddie, C., Bader, P. et al. (33 more authors) (2022) Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Annals of Oncology, 33 (3). pp. 259-275. ISSN 0923-7534 |
| الاتاحة: | https://eprints.whiterose.ac.uk/187848/ https://eprints.whiterose.ac.uk/187848/1/Hayden%20et%20al%20EBMT%20EHA%20CART%20Guidelines%202022.pdf |
| Rights: | cc_by_nc_nd_4 |
| رقم الانضمام: | edsbas.ED61FD1A |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |